Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Percutaneous Transhepatic Biliary Drainage or Endoscopic Retrograde Cholangiography in Treating Participants with Suspected Malignant Bile Duct Obstruction

Liver

This phase III trial studies how well percutaneous transhepatic biliary drainage works versus endoscopic retrograde cholangiography in treating participants with suspected cancerous (malignant) bile duct obstruction. Percutaneous transhepatic biliary drainage is a procedure that uses x-rays to guide a needle through the skin into the bile duct to allow for drainage of the blockage through external tubes. Endoscopic retrograde cholangiography is a procedure that combines the use of a lighted camera that goes down through the mouth and x-rays to diagnose and treat certain problems of the biliary ductal system, and permits drainage of the blockage through internal stents. It is not yet known whether percutaneous transhepatic biliary drainage or endoscopic retrograde cholangiography is most effective in treating participants with suspected malignant bile duct obstruction.
Liver
N/A
Yachimski, Patrick
NCT03172832
VICCGI17104


Derazantinib in Subjects With FGFR2 Gene Fusion Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma

Liver

This pivotal, open-label, single-arm study will evaluate the anti-cancer activity of derazantinib by Objective Response Rate (ORR) by central radiology review as per RECIST v1.1 in subjects with inoperable or advanced intrahepatic cholangiocarcinoma (iCCA) whose tumors harbor FGFR2 gene fusions (by FISH performed by the central laboratory) and who received at least one prior regimen of systemic therapy. Subjects will be dosed orally once per day at 300 mg of derazantinib capsules.
Liver
II
Goff, Laura
NCT03230318
VICCGI1754

A Study to Assess PV-10 Chemoablation of Cancer of the Liver

Liver

This open-label study will evaluate the safety, tolerability, pharmacokinetics and effect on tumor growth following a single intralesional injection of PV-10 in subjects with either (a) hepatocellular carcinoma (HCC) that is not amenable to resection, transplant or other potentially curative therapy or (b) cancer metastatic to the liver.
Liver
I
Brown, Daniel
NCT00986661
VICCMD15133

Suppression and Analysis of Ultrasonic Clutter During Liver Focal Lesion Biopsy

Liver

Liver
N/A
Byram, Brett
VICCGI15145

Yttrium Y 90 Resin Microspheres in Collecting Data from Patients with Liver Cancer That Cannot Be Removed by Surgery for the RESIN Liver Tumor Study

Liver

This research trial studies Yttrium Y 90 resin microspheres in collecting data from patients with liver cancer not capable of being removed by surgery (unresectable) for the radiation-emitting SIR-spheres in non-resectable (RESIN) liver tumor study. The information generated will help doctors better understand treatment patterns involving Y90 therapy, gain additional insights in the long-term outcomes for patients, as well as guide future research for using Y90 therapy, especially for those conditions where data is currently very limited or lacking.
Liver
N/A
Brown, Daniel
NCT02685631
VICCGI1523

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: